SCHEMBL5263887

SCHEMBL5263887

CCOC(=O)[C@H](Cc1ccc(Nc2nc(C)cc3ccncc23)cc1)NC1=C(C2CCCCC2)C(=O)CC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.33
EIF2AK3 Q9NZJ5 1/20 0.33
ELANE P08246 1/20 0.33
KDM4E B2RXH2 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
THRB P10828 1/20 0.32
RAB9A P51151 1/20 0.32
NPR3 P17342 1/20 0.31
P2RX3 P56373 1/20 0.31
PDPK1 O15530 1/20 0.30
NLRP3 Q96P20 1/20 0.30
BDKRB2 P30411 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260905 0.92 ITGB1 (0.35) CYP3A4CYP2C9NPR3P2RX3
SCHEMBL5260895 0.92 ITGB1 (0.35) CYP3A4CYP2C9NPR3P2RX3
SCHEMBL5263890 0.81 CSNK2A1 (0.31) BRAF
SCHEMBL5263897 0.80 PRMT3 (0.32) MEN1KMT2A
SCHEMBL5263895 0.80 PRMT3 (0.32) MEN1KMT2A
SCHEMBL3835521 0.79 ITGB1 (0.46) CYP3A4CYP2C9
SCHEMBL3835880 0.79 ITGB1 (0.46) ELANEKDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL5259895 0.76 ITGB1 (0.35) MEN1KMT2ANPR3
SCHEMBL5259901 0.76 ITGB1 (0.35) MEN1KMT2ANPR3
SCHEMBL5262210 0.75 MEN1 (0.42) BRAFEIF2AK3KDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1332132-B1 ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES UCB PHARMA SA (BE) 2007-10-10 EP disclosed
US-6780874-B2 AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATIVE AGENT CELLTECH R & D LIMITED (GB) 2004-08-24 US disclosed
US-20030229116-A1 ENAMINE DERIVATIVES UCB PHARMA S.A. (BE) 2003-12-11 US disclosed
US-6610700-B2 Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example CELLTECH R & D LIMITED (GB) 2003-08-26 US disclosed
US-20020037909-A1 Enamine derivatives UCB PHARMA S.A. (BE) 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037909-A1 Enamine derivatives CCR1, ITGB2, CCR10 BRAF 2630/4885EIF2AK3 3657/4885ELANE 205/4885
US-20030229116-A1 ENAMINE DERIVATIVES ITGB2, CCR1, CCR10 BRAF 2530/4885EIF2AK3 3761/4885ELANE 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.